March 1, 2024 – Talk Bio

Gritstone Bio Implements Workforce Reduction Following Delay in COVID-19 Vaccine Trial

1 year ago talkbio0Tagged 40%, BARDA, Colorectal cancer vaccine, Contract agreement, COVID-19 vaccine trial, Gritstone Bio, Manufacturing delay, Missed funding, Project NextGen, workforce layoffs

Gritstone Bio, COVID-19 vaccine trial delay, 40% workforce layoffs, Phase 2b CORAL trial, Manufacturing delay, Missed funding, Project NextGen, BARDA contract, Colorectal cancer vaccine

Gritstone Bio Reduces Workforce by 40% Following Delay in Self-Amplifying mRNA COVID-19 Vaccine Trial

1 year ago talkbio0Tagged Deferred, Gritstone Bio

Deferred, Gritstone Bio

Gilead Sciences Receives $210 Million Venture Capital Funding to Expand Trodelvy’s Application in Non-Small Cell Lung Cancer (NSCLC)

1 year ago talkbio0Tagged Application procedure, Capital, Non-Small Cell Lung Carcinoma, Trodelvy, Trodelvy's

Non-Small Cell Lung Carcinoma, Capital, Trodelvy, Trodelvy’s, Application procedure

FogPharma Secures $145M in Series E Funding to Advance Intracellular Peptide Therapy for Solid Tumors

1 year ago talkbio0Tagged FOG-001, Solid Neoplasm

FOG-001, Solid Neoplasm

Kenai Therapeutics Secures $82M Series A to Develop Off-the-Shelf Neuron Replacement Cell Therapy for Parkinson’s

1 year ago talkbio0Tagged RNDP-001

RNDP-001

Novo-founded Orbis Solutions Cracks Macrocycle Synthesis Challenges, Secures $26 Million Funding

1 year ago talkbio0Tagged macrocycle 1

macrocycle 1

Sarepta’s ELEVIDYS Gaining Ground Amidst Anticipation for Expanded Label Approval

1 year ago talkbio0Tagged Age, Child, Commission, ELEVIDYS, Labels (device)

ELEVIDYS, Age, Muscular Dystrophy, Duchenne, Sarepta, Labels (device), Child